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Thyroid disorders constitute one of the most common endocrine disorders in pregnancy. Pregnancy is associated with profound modifications in the regulation of thyroid 
function. The modifications driving unstable regulation of thyroid 
function are increased thyroxine-binding globulin levels due to 
elevated levels of estrogen and human chorionic gonadotropin, 
increase in renal losses of iodine is secondary to increased 
glomerular filtration rate, peripheral metabolism of maternal thyroid 
hormones, and modification in iodine transfer to the placenta also 
undergoes alternations in their regulations [1]. In normal pregnant 
women, the thyroid gland maintains euthyroidism with only minor 
fluctuations in serum thyroxine (T4) and thyroid-stimulating 
hormone (TSH). However, in women with limited thyroid reserve, 
secondary to thyroid autoimmunity, or iodine deficiency, there are 
significant chances of the development of hypothyroidism.
It is estimated that 10–13% of Indian women are hypothyroid 
during the course of pregnancy, whereas the occurrence of unconcealed 
hyperthyroidism is estimated to be around 0.4–1.7% [2]. Thyroid 
dysfunction in pregnant women at both overt and subclinical levels 
significantly increases the risks of pregnancy-related complications. 
Maternal complications include threatened abortion, pre-eclampsia, 
preterm labor, placental abruption, and postpartum hemorrhage.
Fetal complications include the first-trimester spontaneous 
abortions, preterm delivery, low birth weight babies, fetal or neonatal 
hyperthyroidism, intrauterine growth retardation, high rates of 
stillbirth and neonatal deaths, neonatal hyperbilirubinemia, higher 
incidence of neonatal hypothyroidism, and an increased perinatal 
mortality [3]. Hence, understanding the role of maternal thyroid 
dysfunctions to prevent further maternal and neonatal complications 
is crucial. The present study aims to study the impact of maternal 
thyroid dysfunction on maternal and neonatal outcomes in late 
preterm and term deliveries at a tertiary level hospital in India.
METHODS
The present study was a prospective case–control study done in 
a tertiary care public hospital in Western India from July 2017 
to December 2017. Approval was taken from the ethics review 
committee of the hospital along with written informed consent 
from the patients enrolled in the study. The prevalence of thyroid 
disorders in pregnant women delivering at the current facility was 
around 10% as this was a tertiary referral hospital. Sampling was 
done on the principle of convenience sampling as 100 dysthyroid 
mothers following up at the current antenatal clinic at 34 weeks 
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of gestation were enrolled. Hundred euthyroid pregnant mothers 
of the same gestation period were also enrolled in the present 
study. They were followed up biweekly till they delivered, and 
the pregnancy outcome and neonatal outcomes were recorded.
Maternal demographic characteristics, medical, reproductive, 
prenatal history, pregnancy complications such as anemia, 
abortions, pre-eclampsia, postpartum hemorrhage, and need 
for cesarean section were recorded. High-risk pregnant women 
underwent thyroid screening as recommended in the national 
guidelines and the diagnosis of maternal thyroid disease was 
established using TSH levels measured during their first antenatal 
visit for thyroid function test. Classification was done as euthyroid, 
hypothyroid, and hyperthyroid [4]. The reference range used in 
the present study was based on the guidelines of the American 
Thyroid Association (2011) for the diagnosis and management 
of thyroid disease during pregnancy and postpartum [3]. The 
trimester specific normal ranges for TSH are 0.1–2.5 mIU/L 
in the first trimester, 0.2–3 mIU/L in the second trimester, and 
0.3–3 mIU/L in the third trimester [1,3].
Baseline neonatal variables were defined using standard 
definitions and were recorded. The variables included 
gestational age at delivery, sex, small for gestational age (SGA) 
status, and neonatal morbidities such as hyperbilirubinemia, 
respiratory distress syndrome, early-onset sepsis, hypoglycemia, 
hypocalcemia, perinatal asphyxia, necrotizing enterocolitis 
(NEC), and intraventricular hemorrhage were recorded.
Neonatal thyroid function (free T4, TSH) was checked after 
48 h of life as the center did not have facilities for universal 
newborn screening. Neonates were classified as euthyroid, 
hypothyroid, and hyperthyroid based on following gestational 
age and postnatal days. The specific normal values as under were 
1.2–4.4 ng/dl for free T4 and 1.2–21.5 mIU/L at <37 weeks of 
GA whereas for ≥37 weeks of GA, 5.6 ng/dl for free T4, and 
1–10 mIU/L for TSH [5,6].
Infants with abnormal values of TSH underwent a rechecking 
for thyroid status by 2 weeks of life and were finally classified 
as euthyroid, hypothyroid, and hyperthyroid as per the American 
Academy of Pediatricians guidelines [5]. All infants received 
standard nursing care as per unit protocol. They were followed up 
daily till death/discharge from unit whichever was earlier, which 
was proposed as the endpoint of the study.
Obtained information was entered into SPSS version 25 
(SPSS Inc., Chicago, Illinois, United States of America). Relevant 
statistical analysis such as the mean, standard deviation, and 
frequency tables was calculated for the quantitative and qualitative 
variables, respectively. Chi-square test was used to compare 
categorical variables. Continuous variables were analyzed using 
the ANOVA test. p=0.05 was considered statistically significant.
RESULTS
Four thousand seven hundred and eighty-nine mothers visited the 
antenatal clinic in the facility for over 6 months of the study period. 
Enrollment of 100 consecutive dysthyroid mothers at 34 weeks 
in the study group was done and 100 euthyroid mothers were 
enrolled at 34 weeks in the control group. Three of these mothers 
were on pre-existing hypothyroid treatment with levothyroxine 
while the remaining was diagnosed in the first-trimester screening. 
Their infants were enrolled in the study after delivery. Mothers 
were categorized into three groups according to thyroid function 
test results: 97 were hypothyroid and three were hyperthyroid. 
Maternal demographic characteristics and morbidities are shown 
in Table 1.
The mean maternal age was comparable in all three 
groups (26.64±5.42 years for euthyroid, 27.15±4.33 years for 
hypothyroid, and 30.33±1.53 years for hyperthyroid mothers, 
respectively). The mean maternal weight was 48.77±7.32 kg in 
euthyroid, 50.16±6.96 kg in hypothyroid, and 46.67±6.66 kg 
in hyperthyroid group, respectively. There was no significant 
difference in age and weight parameters in the three groups.
Associated maternal morbidities in the hypothyroid group 
included pre-eclampsia (7.2% vs. 3%; p=0.121) and GDM (11.3% 
vs. 2%; p=0.026). The need for cesarean delivery was significantly 
higher in the hypothyroid group (36.1% vs. 19%; p=0.025). The 
most common indication for cesarean section was the failure of 
induction of labor. There was no significant difference in the 
incidence of anemia (53.6% vs. 43%; p=0.279), PPH (3.1% vs. 
0%; p=0.198), abortions (17.5% vs. 14%; p=0.559), and MSAF 
(8.2% vs. 5%; p=0.133). The number of hyperthyroid mothers 
was very small for any valid comparisons. Mean TSH values were 
1.3910±0.290 mIU/L for euthyroid, 4.131±1.455 for hypothyroid, 
and 0.833±0.208 for hyperthyroid mothers, as shown in Table 1.
Neonatal outcomes in different groups are shown in Table 2. 
Hypothyroid mothers delivered more often in between 34 
and 37 weeks than euthyroid mothers (31% vs. 21%; p=0.03). 
Hypothyroid mothers also delivered smaller babies: SGA 
(32% vs. 15%; p=0.01). There was no significant difference in 
neonatal morbidities such as RDS (4.1% vs. 2%; p=0.651), sepsis 
(3.1% vs. 2%; p=0.852), hypoglycemia (1% vs. 0%; p=0.586), 
NEC (1% vs. 0%; p=0.586), TTNB (1% vs. 0%; p=0.586), need 
for resuscitation (4.1% vs. 4%; p=0.938), perinatal asphyxia 
(5.2% vs. 1%; p=0.221), and neonatal hyperbilirubinemia 
(23.7% vs. 19%; p=0.480).
Mean TSH values were 3.437±1.387 mIU/L, 3.949±2.379 mIU/L, 
and 4.076±1.246 mIU/L for infants of euthyroid, hypothyroid, 
and hyperthyroid mothers, respectively. Mean T4 values were 
1.778±0.079 ng/dl for infants of euthyroid mothers, 1.530±0.535 ng/
dl for the baby of hypothyroid mothers, and 1.306±0.1 ng/dl for 
infants of hyperthyroid mothers. There was no significant difference 
in the TSH (p=0.17). However, free T4 values did show a significant 
variation (p=0.015) in the infants born to mothers belonging to 
the various groups; although none of the babies were rescreened 
or treated as their individual TSH and free T4 values were within 
normal ranges.
DISCUSSION
Thyroid disorders are the most common endocrine disorders 
seen in pregnancy. It is recommended to screen women early 
in the pregnancy for thyroid dysfunction as these disorders are 
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common, treatable and pose a special risk for pregnancy and the 
developing fetus. Screening for thyroid dysfunction is not only 
important in pregnant women but also in women who wish to 
conceive because the status of the regulation of thyroid hormone 
is directly related to fetal brain development. Thyroid disorders 
may be overlooked in pregnancy due to non-specific symptoms 
and hypermetabolic state of pregnancy. Physiological changes 
occurring during pregnancy can mimic thyroid disease.
The prevalence of thyroid disorders during pregnancy has a wide 
geographic variation. There is a paucity of data on the prevalence 
of thyroid disorders in Indian pregnant women; few reports show 
a prevalence of 10–13% among Indian pregnant populations [2]. 
Sahu et al. have reported a prevalence of hypothyroidism as 6.47% 
in pregnant women [7]. Ajmani et al. reported a prevalence of 
12% and 1.25%, respectively, for hypo- and hyper-thyroidism in 
the pregnant women in his study [8]. The most common cause of 
hypothyroidism in pregnancy in developing countries like India 
is iodine deficiency. Hashimoto’s thyroiditis is the most common 
cause of hypothyroidism in iodine-sufficient areas [4].
There were several important observations in the present study. 
Gestational diabetes commonly coexisted with hypothyroidism 
(11%). The need for cesarean delivery was higher in hypothyroid 
patients as they failed induction of labor (36.1%). Among the 
neonatal outcomes, the hypothyroid patients had a significantly 
higher incidence of late preterm delivery (31%) and had a higher 
incidence of SGA in infants (32%). In the study by Ajmani et al., the 
incidences of comorbidities in pregnant women with hypothyroidism 
such as pre-eclampsia (22.3%), preterm births (33.3%), and SGA 
(25%) were reported which are non-significant in comparison to 
the present study [8]. The need for cesarean section (41%) was 
higher than that found in the present study. Similarly, in the study 
by Sahu et al., the comorbidities in hypothyroid mothers and their 
infants like pre-eclampsia (9.8%) were higher, but the incidence 
of preterm delivery (10.3%) and SGA (13.8%) was lower than 
the population from the present study [7]. Saraladevi et al. found 
that that pre-eclampsia was a common situation in hypothyroid 
mothers (14.28%), which was higher than the present study, but the 
incidence of SGA (6.25%) was much lower [9].
Table 1: Maternal demographics, morbidity, and TSH values
Maternal variables Euthyroid (n=100) Hypothyroid (n=97) Hyperthyroid (n=3) p‑value
Age (Mean±SD) 26.64±5.417 27.15±4.333 30.33±1.528 0.368
Weight (Mean±SD) 48.77±7.314 50.16±6.961 46.67±6.658 0.515
Pre-eclampsia 3 (3%) 7 (7.2%) 0 0.121
GDM 2 (2%) 11 (11.3%) 0 0.026
Anemia 14 (14%) 17 (17.5%) 0 0.599
PPH 0 3 (3.1%) 0 0.198
Abortions 14 (14%) 17 (17.5%) 0 0.599
MSAF 5 (5%) 8 (8.2) 1 (33.3%) 0.133
Bad obstetric history 8 (8%) 7 (7.2%) 1 (33.3%) 0.260
Mode of delivery
ND 81 (81%) 60 (61.9) 3 (100%) 0.025
LSCS 19 (19%) 35 (36.1) 0
Instrumental delivery 0 2 (2.1%) 0
TSH (mIU/l) 1.3910±0.290 4.1312±1.455 0.8333±0.208
GDM: Gestational diabetes mellitus, PPH: Postpartum hemorrhage, MSAF: Meconium‑stained amniotic fluid, ND: Normal delivery, LSCS: Lower segment cesarean section, 
TSH: Thyroid‑stimulating hormone
Table 2: Neonatal morbidities and TSH values
Neonatal variables Euthyroid (n=100) Hypothyroid (n=97) Hyperthyroid (n=3) p‑value
Late preterm 21 (21%) 30 (31%) 0 0.03
SGA 15 (15%) 31 (32%) 0 0.01
RDS 2 (2%) 4 (4.1%) 0 0.651
Sepsis 2 (2%) 3 (3.1%) 0 0.852
Hypocalcemia 0 0 0
Hypoglycemia 0 1 (1%) 0 0.586
NEC 0 1 (1%) 0 0.586
TTNB 0 1 (1%) 0 0.586
Required resuscitation 4 (4%) 4 (4.1%) 0 0.938
Asphyxia 1 (1%) 5 (5.2%) 0 0.221
Jaundice 19 (19%) 23 (23.7%) 0 0.480
TSH (mIU/L) 3.437±1.387 3.949±2.379 4.076±1.246 0.170
Free T4 1.778±0.709 1.530±0.535 1.306±0.100 0.015
SGA: Small for gestational age, RDS: Respiratory distress syndrome, NEC: Necrotizing enterocolitis, TTNB: Transitory tachypnea of newborn, TSH: Thyroid‑stimulating hormone
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Thyroid dysfunction in newborns of dysthyroid mothers 
was negligible as all babies had normal thyroid hormone levels. 
Transient thyroid dysfunction up to 8 weeks of age was reported by 
Ozdemir et al. in their study. They also reported a greater incidence 
of prematurity, respiratory distress, and suspect sepsis in infants born 
to dysthyroid mothers [10]. Although hyperthyroidism in pregnancy 
is uncommon, the effects on both mother and child are critical. 
However, in the present study, authors were unable to derive any 
significant findings that might have further established the direct link 
between the regulation of maternal thyroid function and its maternal 
and neonatal outcomes. Hypothyroidism is a significant comorbidity 
in high-risk pregnant women which can have a significant impact on 
maternal and fetal outcomes. One of the major limitations of the 
present study was the number of hyperthyroid mothers enrolled, 
which was very small since the disease is comparatively infrequent.
CONCLUSION
Knowledge of the coexisting morbidities such as gestational 
diabetes, prematurity, growth retardation, and greater need 
for cesarean births can guide us in handling adverse maternal 
and neonatal outcomes; however, larger studies are needed for 
establishing an association between dysthyroidism. Abnormalities 
in thyroid function tests, however, remain uncommon in infants 
born to dysthyroid mothers. Early screening and optimum 
treatment of thyroid disorders are extremely vital for optimum 
maternal and neonatal health outcomes.
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